TITLE

Drug costs and utilization after implementation of a posaconazole prophylaxis protocol in adults with acute myelogenous leukemia

AUTHOR(S)
NEMEROVSKI, CARRIE W.; MACKLER, EMILY R.; DEPESTEL, DARYL D.; COLLINS, CURTIS D.; WELCH, KATHLEEN S.; STEVENSON, JAMES G.
PUB. DATE
February 2010
SOURCE
American Journal of Health-System Pharmacy;2/15/2010, Vol. 67 Issue 4, p295
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Purpose. Drug costs and utilization after implementation of a posaconazole prophylaxis protocol in adults with acute myelogenous leukemia (AML) were studied. Methods. Adult patients who initiated induction or reinduction chemotherapy for the treatment of AML between December 1, 2006, and March 31, 2008, at a tertiary care hospital were included in this retrospective cohort study. Patients were divided into two groups: preprotocol (treated before June 1, 2007) and postprotocol (treated on or after June 1, 2007). Medical charts, including pharmacy and laboratory data, were reviewed for all patients. Outcomes measured included antifungal and antibacterial drug costs and utilization and total pharmacy costs. Results. A total of 66 patients were evaluated (33 in each group). Baseline characteristics, except patient age, were similar between groups. Each group incurred similar costs and utilized resources for similar periods of time as evidenced by similar lengths of stay, duration of neutropenia, and mortality. Antibacterial costs, total pharmacy costs, and other utilization outcomes were also similar between the two groups. Alterations to antifungal management strategy occurred more often in the postprotocol group (33% versus 58%, p = 0.048). Conclusion. Implementation of a posaconazole protocol did not significantly alter antifungal or antibacterial drug costs or utilization or total pharmacy costs. Prophylactic posaconazole was frequently changed to alternative antifungal therapy due to an adverse drug event, perceived lack of efficacy, avoidance of a drug interaction, or inability to tolerate oral intake.
ACCESSION #
47924082

 

Related Articles

  • Effect of topical oral G-CSF on oral mucositis: a randomised placebo-controlled trial. Karthaus, M; Rosenthal, C; Huebner, G; Paul, H; Elser, C; Hertenstein, B; Krauter, J; Scharmann, T; Geissler, R G; Heil, G; Ganser, A // Bone Marrow Transplantation;10/15/98, Vol. 22 Issue 8, p781 

    Oral mucositis is a dose-limiting toxicity of intensive chemotherapy. It is caused directly by the cytotoxic effect of chemotherapeutic agents and indirectly by sustained neutropenia. Severe oral mucositis is an important predisposing factor for life-threatening septic complications during...

  • Positive impact of selective outpatient management of high-risk acute myelogenous leukemia on the incidence of septicemia. TY Halim; KW Song; MJ Barnett; DL Forrest; DE Hogge; SH Nantel; TJ Nevill; JD Shepherd; CA Smith; HJ Sutherland; CL Toze; JC Lavoie // Annals of Oncology;Jul2007, Vol. 18 Issue 7, p1246 

    Background: Curative intent chemotherapy for acute myelogenous leukemia (AML) leads to prolonged severe neutropenia, during which patients are highly susceptible to infection. Traditionally these high-risk patients were treated as inpatients. Our center recently implemented a selective...

  • A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trial. Sierra, Jorge; Szer, Jeffrey; Kassis, Jeannine; Herrmann, Richard; Lazzarino, Mario; Thomas, Xavier; Noga, Stephen J.; Baker, Nigel; Dansey, Roger; Bosi, Alberto // BMC Cancer;2008, Vol. 8, Special section p1 

    Background: Patients with acute myeloid leukemia (AML) are often neutropenic as a result of their disease. Furthermore, these patients typically experience profound neutropenia following induction and/or consolidation chemotherapy and this may result in serious, potentially lifethreatening,...

  • Erythematous eruption in a man with acute myeloid leukemia. Tay, Jason // CMAJ: Canadian Medical Association Journal;9/17/2002, Vol. 167 Issue 6, p672 

    Presents the case of a man with type two diabetes mellitis who was diagnosed with acute myeloid leukemia. Conventional induction chemotherapy which was given to the patient; Bone marrow suppression resulting from the treatment, which may cause profound neutropenia; Skin rash which was developed...

  • Clofarabine.  // Reactions Weekly;10/22/2011, Issue 1374, p14 

    The article describes the case of a 65-year-old man who developed acute renal failure and proteinuria while on clofarabine therapy for a relapse of acute myeloid leukaemia (AML).

  • Tocilizumab.  // Reactions Weekly;2/11/2012, Issue 1388, p29 

    The article describes the case of a 40-year-old woman who underwent stem cell transplantation for acute myeloid leukaemia and developed exacerbated hyperbilirubinaemia following the initial intravenous infusion of tocilizumab.

  • Intensive Chemotherapy for Acute Myelogenous Leukemia. Gale, Robert Peter; Foon, Kenneth A.; Cline, Martin J.; Zighelboim, Jacob // Annals of Internal Medicine;Jun81, Vol. 94 Issue 6, p753 

    Presents a study that examined remission rates in a group of patients with acute myelogenous leukemia treated with high-dose induction chemotherapy. Medical history of the patients; Identification of factors that affect remission; Results and discussion.

  • Duration of second complete remission compared with first complete remission in patients with acute myeloid leukemia. Lee, S; Tallman, M S; Oken, M M; Cassileth, P A; Bennett, J M; Wiernik, P H; Rowe, J M // Leukemia (08876924);Aug2000, Vol. 14 Issue 8, p1345 

    The prognosis for patients with acute myeloid leukemia in first relapse is generally poor. The ability to induce a second complete remission (CR) with the same chemotherapy used in initial induction therapy is limited. Remission inversion rate, defined as achieving a longer second CR than the...

  • Early onset of chemotherapy can reduce the incidence of ATRA syndrome in newly diagnosed acute promyelocytic leukemia (APL) with low white blood cell counts: results from APL 93 trial. de Botton, S.; Chevret, S.; Coiteux, V.; Dombret, H.; Sanz, M.; San Miguel, J.; Caillot, D.; Vekhoff, A.; Gardembas, M.; Stamatoulas, A.; Conde, E.; Guerci, A.; Gardin, C.; Fey, M.; Cony Makhoul, D.; Reman, O.; de la Serna, J.; Lefrere, F.; Chomienne, C.; Degos, L. // Leukemia (08876924);Feb2003, Vol. 17 Issue 2, p339 

    Treatment combining ATRA and chemotherapy (CT) has improved the outcome of APL patients, by comparison with CT alone. ATRA syndrome is a life-threatening complication of ATRA treatment whose prophylaxis remains somewhat controversial. In APL93 trial, newly diagnosed APL patients ≤65 years...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics